Arihant Capital Markets (‘Manager to the Offer’) on behalf of Ipca Laboratories (‘Acquirer’) has informed about this Post Offer Public Announcement to the shareholders of Krebs Biochemicals and Industries (‘Target Company’), pursuant to Regulation 18 (12) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations 2011, as amended (SEBI SAST Regulations) In respect of Open Offer to acquire up to 35,73,515 Equity Shares, constituting 26% of the fully diluted voting Equity Share Capital (the ‘Offer’) of Target Company. The Detailed Public Statement (‘DPS) with respect to the aforementioned Offer was published on February 24, 2015.
The above information is a part of company’s filings submitted to BSE.
